Altor BioScience Stock

Altor BioScience researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases.

Sign up today and learn more about Altor BioScience Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Altor BioScience Stock

Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases. It offers STAR Fusion Reagents for diagnosing and targeting cancer and viral infections; and STAR Multimer Reagents for research and design of anti-cancer and anti-viral vaccine. The company's products in clinical stage include a monoclonal antibody that prevents and treats staphylococcal infections in premature neonates; and STAR-Ck or ALT-801, an anti-cancer drug. It also has products in various development stages, such as fusion agents for cancer and viral infections, immunotherapeutics against staphylococcal infections, gene therapy for cancer, and multimers reagents. In addition, the company provides products for detecting novel disease targets. Its products are used in the direct and quantitative detection of endogenous peptide antigens' presentation on diseased cells and tissues. The company was founded in 2002 and is headquartered in Miramar, Florida.

Funding History

August 2008$15.0M
October 2009$1.2M
March 2010$647K
July 2010$1.6M
January 2011$10.3M
July 2012$11.3M
March 2013$5.5M
June 2015$10.7M
July 2016$20.0M
March 2017$30.3M


President and CEO

Hing C. Wong

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: